Eden Research Share Discussion Threads

[neutralpov] 18/5/2021 11:46

Hahahahhahahahahhahahahahhhh @ irrelevant ramping BS

Anyone who falls for this deserves what they get.

[supersonico] 18/5/2021 06:16

Spadey,

Looks to me like the Corteva deal is following the Cedroz 3year timeline.

21st Dec 2016 Eastman commercialisation agreement for nematicide.

16th Oct 2019 Cedroz Approval

............................................

12th May 2021 Milestone Agreement signed with Corteva

'The companies are committed to working together to register the final product candidate with the aim of initially launching the Product in the European Union, the UK and Serbia in time for the 2024 growing season'

[neutralpov] 18/5/2021 05:14

spadeychops 18 May '21 - 04:11 - 9395
"And what can Corteva to realise “ Corteva and Eden have defined a joint regulatory strategy to register the Product and enable entry into the market in the shortest time possible.”"

Do you get paid even when your scribbling is unintelligible and grammatically unsound?

And it's already "in" the share price

[neutralpov] 17/5/2021 23:47

> so wonder when they expect

Hahahhahahahahhahhhhaaaa!! I will do myself a mischief, laughing this much.

These rampers are truly without any shame whatever.

[neutralpov] 17/5/2021 23:00

I guess this disease is a bit like religion.

The idiot gets into it with zero evidence let alone proof.

But to get the idiot out of it, near impossible, the idiot demands impossible levels of proof.

Rather similar to being a holder of EDEN.L

;-D

[neutralpov] 17/5/2021 22:59

erinvale1 17 May '21 - 17:05 - 9389
> It is surprising - and worrying - that no-one has made a bid for Eden.

Only to idiots.

Nothing surprising - read what I've been writing for weeks.

Only worrying to PIs who are still invested - they're idiots by definition.

HTH (Hope That Helps)

[supersonico] 17/5/2021 18:03

It's lucky for Mr £60K that Uhuy did not mention ££ or he would have had to pay a whole lot more for his 400K.

SN.

[erinvale1] 17/5/2021 17:05

It is surprising - and worrying - that no-one has made a bid for Eden. The 10% decline post the Corteva RNS is an ideal opportunity.

[investingisatrickygame] 17/5/2021 16:54

Super,

it is easily mentionable as it was all in the Placing RNS last year.

Success needs to be amplified at Eden as regulatory approval is the first milestone to commercial success.

Build and they will come.

Tell and they will invest!!!!

Eden hasn't demonstrated their ability and understanding of what is needed to ensure people invest. I'm hoping the next RNS corrects this and that Hawthorn/Cenkos/someone shows them how to do this otherwise these commercial and regulatory success go totally unnoticed and misunderstood. That could, with a pending book of some substance, lead to ANO coming in with a ridiculous bid that fed up shareholders deem acceptable.

[neutralpov] 17/5/2021 16:19

Target .... 0p

[neutralpov] 17/5/2021 16:18

Hey suckers, time to

FILL UP!

FILL YER BOOTS!!

CHEAP AS CHIPS!!!

etc.

not to forget

CORTEVA
CORTEVA
CORTEVA!!!!!

(snicker)

[neutralpov] 17/5/2021 16:11

supersonico 17 May '21 - 15:55 - 9381
> Very disappointing that they make such little effort to make even minimal projections.

So is it because "they" are incompetent, lazy sitting on their inflated salaries for doing F-All, or because they are scared of the regulator re forward-looking statements?

)sigh(

[neutralpov] 17/5/2021 16:09

Investingisatrickygame 17 May '21 - 15:14 - 9380
[SNIP LOTS OF UTTER RUBBISH]
> My calculation says that ...

... you, Investing, are a cheating, lying, thieving ramper, paid to "up" the share price of this dog of a stock.

[SNIP EVEN MORE TOSH]

(popcorn)

[supersonico] 17/5/2021 15:55

Investing,
It would be good to have that info but clearly he was unable to mention it just as he has been unable to mention the TT delay despite many opportunities to do so.

Very disappointing that they make such little effort to make even minimal projections.

[investingisatrickygame] 17/5/2021 15:14

Super,

More than anything, I think what we need now is a strong re-iteration of Eden's pipeline and potential business split by A)Mevalone and B) Cedroz. These numbers will be rising in time to account as the new regulatory approvals are granted.

I think we should also make it clear to everyone that Cedroz (most likely) means an immediate product sale and so Eden is off and running with each new country approval. We do know that Mevalone is weather dependent and sales with react accordingly. However, with storage apples I assume this variable doesn't apply and if not, sales would occur like Cedroz. This should be clarified to investors too.

Eden has to put right the wrong's of last week and that means making sure the investment community understands who Eden are, the problems they are solving and the highly significant relevance and numbers for the regulatory approvals they have had. So aggregated numbers by product, timeline to estimated targets and hoped for sales in 2021 and 2022 to give an indication of hope/expectation whilst also laying down a marker of the reality of sales in Cedroz.

As for the Corteva success, Eden told us nothing other than the global market size of seed treatments which means nothing unless Eden intends to satisfy that whole market, which clearly they do not.

So, what is the value of the deal; is it still up to €40 million for Europe alone and the same guidance here for timelines, hoped fors etc.

My calculation says that if you add the regulatory approvals for the two products and add in Corteva seeds, then Eden's estimated market to satisfy in three years is €214 million. That is HUGE compared to where we are now. Truly transformational.

You can take a % of that if you wish, not a problem, still far removed positively from where we are now.

If Eden did €10 million of sales in the next 12 months, that is very significant from the last two years performance.

Eden needs to showcase this very real possibility of their own numbers and have everyone who knows of views Eden, understand the very real possibilities for Eden as a technology company operation in a global market aiding global agriculture.

These are the relevant numbers and messages that need to be communicated so that investors appropriate a more relevant valuation to Eden's share price.

[neutralpov] 17/5/2021 13:55

Always funny, the way the ramper(s) talk to themself (each other).

;D

[supersonico] 16/5/2021 19:16

This woman.. India based Hemlata makes multiple re-posts of Corteva news and now appreciates
Eden's Linked-in post.

[supersonico] 16/5/2021 12:15

Looking into it Spadey,

Bio pesticide Research in India
Research work in biopesticides is mainly funded by the Government Department of Bio Technology. The Indian Council of Agricultural Research, Bangalore Indian Institute of Horticulture Research, Hesaragatta, Bangalore Central Integrated Pest Management Centre (CIPMC), White field, Bangalore Central Institute for Cotton Research (CICR), Nagpur Bio pesticides companies in India: